MYLK3 and breast cancer: Co-treatment with calmodulin (CaM), a primary MLCK activator, counteracted the BC dilation induced by the 3 compounds, and CaM completely prevented the inhibition of [3H]-TA clearance induced by bosentan and DCA (Fig. 10D).